Metformin inhibits non-small cell lung cancer via lncRP11-242D8.1
Abstract
OBJECTIVES: Metformin may exert anticancer effects in non-small cell lung cancer (NSCLC) by influencing long non-coding RNAs involved in the disease's pathology. The Study aimed to investigate the inhibitory effect of metformin on NSCLC by modulating the expression of lncRP11-242D8.1.
METHODS: Inflammation and apoptosis levels in NSCLC were assessed at the molecular level using immunofluorescence, RT-qPCR, and ELISA. Metformin's effects on NSCLC in vitro were evaluated by CCK8, scratch wound healing, Transwell, colony formation, flow cytometry assays, etc. Bioinformatics analysis and molecular experiments were combined to investigate the mechanisms involving metformin and lncRP11-242D8.1.
RESULTS: Low expression of lncRP11-242D8.1 is positively correlated with increased inflammation and decreased apoptosis, leading to poor prognosis in NSCLC. Treatment with metformin in the H1299 cell model improved this trend.
CONCLUSION: This study suggests that metformin treats NSCLC by upregulating lncRP11-242D8.1 expression, which inhibits inflammation and promotes apoptosis, offering a new perspective for clinical treatment.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.